| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
1 Division of Hematology/Oncology, Department of Medicine, Cedars-Sinai Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California
2 Division of Nuclear Medicine, Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, California
The purpose of this study was to evaluate the clinical utility of whole-body PET with 18F-FDG in patients with multiple myeloma and related monoclonal diseases. Methods: Between July 1, 1996, and July 2000, 98 18F-FDG PET scans were obtained for 66 patients, with 25 patients having 2 or more scans. The results were compared with routine clinical and staging information, including CT and MRI scans, as indicated. Of the 66 patients, 16 had previously untreated active myeloma, 14 had monoclonal gammopathy of undetermined significance (MGUS), 10 had disease in remission, and 26 had relapsing disease. Results: Negative whole-body 18F-FDG PET findings reliably predicted stable MGUS. Of the 14 MGUS patients with follow-up of 3–43+ mo, myeloma has developed in only 1 (7%), at 8 mo. Conversely, the 16 previously untreated patients with active myeloma all had focal or diffusely positive scan findings. Four (25%) of 16 previously untreated patients with positive 18F-FDG PET findings had negative full radiologic surveys. Another 4 (25%) of 16 patients had focal extramedullary disease. This was confirmed by biopsy or other imaging techniques. Extramedullary uptake also occurred in 6 (23%) of 26 patients with relapse. This extramedullary uptake was a very poor prognostic factor both before treatment and at relapse. For example, median survival was 7 mo for patients with disease relapse. Persistent positive 18F-FDG PET findings after induction therapy predicted early relapse. In 13 (81%) of 16 patients with relapsing disease, new sites of disease were identified. The 18F-FDG PET results were especially helpful in identifying focal recurrent disease in patients with nonsecretory or hyposecretory disease amenable to local irradiation therapy, which was used in 6 patients. Conclusion: Whole-body 18F-FDG PET provides important prognostic information, which is clinically useful and complementary to conventional methods of evaluating plasma cell disorders. 18F-FDG PET is a unique tool for evaluation of nonsecretory myeloma. Residual or recurrent disease after therapy, especially extramedullary disease, is a poor prognostic factor.
Key Words: PET • 18F-FDG • multiple myeloma • prognosis • high risk
This article has been cited by other articles:
|
|
 |
|
  P.-Y. Salaun, T. Gastinne, E. Frampas, C. Bodet-Milin, P. Moreau, and F. Bodere-Kraeber FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma Haematologica, August 1, 2008; 93(8): 1269 - 1271. [Full Text] [PDF]
|
|
|
|
 |
|
 M HORGER, P PEREIRA, C D CLAUSSEN, L KANZ, R VONTHEIN, B DENECKE, and C DRIESSEN Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters Br. J. Radiol., May 1, 2008; 81(965): 386 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fonti, B. Salvatore, M. Quarantelli, C. Sirignano, S. Segreto, F. Petruzziello, L. Catalano, R. Liuzzi, B. Rotoli, S. Del Vecchio, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma J. Nucl. Med., February 1, 2008; 49(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ghesani, S. Goel, M. Meka, S. Cohen, A. Chang, and P. Maslin Multiple Myeloma Presenting With [18F]Fluorodeoxyglucose Avid Liver Lesions Diagnosed on Positron Emission Tomography Scan J. Clin. Oncol., November 20, 2007; 25(33): 5319 - 5320. [Full Text] [PDF]
|
|
|
|
|
|
E. Zamagni, C. Nanni, F. Patriarca, E. Englaro, P. Castellucci, O. Geatti, P. Tosi, P. Tacchetti, D. Cangini, G. Perrone, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma Haematologica, January 1, 2007; 92(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dankerl, P. Liebisch, G. Glatting, C. Friesen, N. M. Blumstein, D. Kocot, C. Wendl, D. Bunjes, and S. N. Reske Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience Radiology, December 19, 2006; (2006) 2422051980. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. H. Kuo and D. W. Cheng Artifactual Spinal Metastases Imaged by PET/CT: A Case Report J. Nucl. Med. Technol., December 1, 2005; 33(4): 230 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Even-Sapir Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Duet, P. Tran Ba Huy, M. Wassef, and F. Liote Plasma Cell Problems: CASE 3. Plasmacytoma Mimicking a Paraganglioma of the Skull Base: Diagnostic Value of Somatostatin Receptor Scintigraphy J. Clin. Oncol., May 1, 2005; 23(13): 3143 - 3145. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Z. Badros, P. G. Richardson, A. Kassarjian, and W. Jing Case 38-2004: A Large Tumor of the Skull N. Engl. J. Med., April 14, 2005; 352(15): 1610 - 1610. [Full Text] [PDF]
|
|
|
|
|
|
C.S. Chim, G.C. Ooi, F. Loong, A.W.M. Au, and A.K.W. Lie Side Effects and Good Effects from New Chemotherapeutic Agents: CASE 3. Bortezomib in Primary Refractory Plasmacytoma J. Clin. Oncol., April 1, 2005; 23(10): 2426 - 2428. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Bredella, L. Steinbach, G. Caputo, G. Segall, and R. Hawkins Value of FDG PET in the Assessment of Patients with Multiple Myeloma Am. J. Roentgenol., April 1, 2005; 184(4): 1199 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hooft, A. A. M. van der Veldt, P. J. van Diest, O. S. Hoekstra, J. Berkhof, G. J. J. Teule, and C. F. M. Molthoff [18F]Fluorodeoxyglucose Uptake in Recurrent Thyroid Cancer Is Related to Hexokinase I Expression in the Primary Tumor J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 328 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pace, S. Del Vecchio, M. Salvatore, R. C. Walker, E. Angtuaco, R. Sethi, A. Fassas, and B. Barlogie Technetium 99m Sestamibi in Multiple Myeloma * Dr Walker and colleagues respond: Radiology, January 1, 2005; 234(1): 312 - 313. [Full Text] [PDF]
|
|
|
|
|
|
B. G.M. Durie, J. Jacobson, B. Barlogie, and J. Crowley Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials J. Clin. Oncol., May 15, 2004; 22(10): 1857 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Meyer, L. C. Hofbauer, A. Neubauer, M. Schoppet, C. M. Lu, R. C. Walker, B. Barlogie, and J. Shaughnessy Jr. DKK1 in Multiple Myeloma N. Engl. J. Med., April 1, 2004; 350(14): 1464 - 1466. [Full Text] [PDF]
|
|
|
|
|
|
C.S. Chim, G.C. Ooi, F. Loong, and R. Liang Unusual Presentations of Hematologic Malignancies: CASE 1. Solitary Bone Plasmacytoma: Role of Magnetic Resonance Imaging and Positron Emission Tomography J. Clin. Oncol., April 1, 2004; 22(7): 1328 - 1330. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
